Iovance Biotherapeutics, Inc.
IOVA
$3.89
-$0.15-3.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 296.98M | 300.80M | 301.18M | 359.71M | 323.78M |
| Total Receivables | 82.45M | 66.76M | 59.94M | 70.94M | 69.34M |
| Inventory | 51.68M | 51.71M | 49.83M | 65.55M | 51.52M |
| Prepaid Expenses | 11.58M | 9.82M | 11.55M | 15.89M | 12.38M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | 559.00K | -- |
| Total Current Assets | 442.69M | 429.09M | 422.50M | 512.65M | 457.02M |
|
|
|||||
| Total Current Assets | 442.69M | 429.09M | 422.50M | 512.65M | 457.02M |
| Net Property, Plant & Equipment | 177.01M | 175.41M | 172.42M | 162.49M | 164.28M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 279.32M | 285.21M | 296.25M | 285.36M | 282.40M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 14.15M | 15.24M | 16.26M | 6.25M | 6.73M |
| Total Assets | 913.17M | 904.95M | 907.44M | 966.74M | 910.43M |
|
|
|||||
| Total Accounts Payable | 22.16M | 31.24M | 32.00M | 28.49M | 27.51M |
| Total Accrued Expenses | 104.71M | 82.91M | 78.05M | 77.49M | 75.19M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 5.04M | 7.28M | 8.07M | 9.50M | 12.90M |
| Total Finance Division Other Current Liabilities | 6.45M | 4.36M | 11.03M | 7.22M | 6.75M |
| Total Other Current Liabilities | 6.45M | 4.36M | 11.03M | 7.22M | 6.75M |
| Total Current Liabilities | 138.36M | 125.79M | 129.16M | 122.69M | 122.34M |
|
|
|||||
| Total Current Liabilities | 138.36M | 125.79M | 129.16M | 122.69M | 122.34M |
| Long-Term Debt | -- | -- | -- | -- | 1.00M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 44.40M | 45.21M | 45.10M | 44.22M | 44.37M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 31.83M | 31.67M | 34.70M | 31.96M | 32.32M |
| Total Liabilities | 214.59M | 202.66M | 208.95M | 198.88M | 200.02M |
|
|
|||||
| Common Stock & APIC | 3.46B | 3.39B | 3.29B | 3.26B | 3.10B |
| Retained Earnings | -2.78B | -2.70B | -2.61B | -2.50B | -2.38B |
| Treasury Stock & Other | 16.44M | 16.10M | 20.86M | 6.29M | -1.05M |
| Total Common Equity | 698.58M | 702.29M | 698.49M | 767.86M | 710.40M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 2.00K | 2.00K | 2.00K | 2.00K | 3.00K |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 2.00K | 2.00K | 2.00K | 2.00K | 3.00K |
|
|
|||||
| Total Common Equity | 698.58M | 702.29M | 698.49M | 767.86M | 710.40M |
| Total Preferred Equity | 2.00K | 2.00K | 2.00K | 2.00K | 3.00K |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 698.58M | 702.29M | 698.49M | 767.87M | 710.41M |
|
|
|||||